What Is Dovato (Dolutegravir/Lamivudine)? Uses, Dosage, and What You Need to Know in 2026

Dovato (dolutegravir/lamivudine) is a once-daily prescription medication used to treat HIV-1 infection in adults and adolescents 12 years and older weighing at least 55 pounds (25 kg). It was the first FDA-approved two-drug, single-tablet HIV treatment, approved on April 8, 2019.

Before Dovato, the standard HIV treatment required three or four drugs. Dovato's two-drug approach offers comparable efficacy with fewer medications — which may mean fewer potential side effects and fewer drug interactions for eligible patients.

What Does Dovato Treat?

Dovato is FDA-approved to treat HIV-1 infection (the most common type of HIV). It is indicated for two groups of patients:

• Treatment-naive patients: Adults and adolescents who have never taken HIV medication before and have no known resistance to dolutegravir or lamivudine.
• Virologically suppressed patients switching regimens: Adults and adolescents already on a stable HIV regimen with undetectable viral load (HIV-1 RNA < 50 copies/mL), no history of treatment failure, and no known resistance to either drug in Dovato.

Dovato does not cure HIV or AIDS. It works by keeping the virus suppressed so that patients can live healthy lives and reduce the risk of transmitting HIV to others.

What's in Dovato?

Each Dovato tablet contains two active ingredients:

• Dolutegravir 50 mg: An integrase strand transfer inhibitor (INSTI) that blocks the HIV integrase enzyme, preventing viral DNA from integrating into the host cell's chromosomes.
• Lamivudine 300 mg: A nucleoside analog reverse transcriptase inhibitor (NRTI) that blocks the reverse transcriptase enzyme, preventing HIV from converting its RNA into DNA.

These two drugs work at different points in the HIV replication cycle, creating a robust two-pronged attack against the virus.

How to Take Dovato

Dovato's dosing instructions are straightforward:

• Dose: One tablet (dolutegravir 50 mg / lamivudine 300 mg) once daily.
• Food: Can be taken with or without food — no meal requirement.
• Timing: Take at approximately the same time each day. Consistency helps maintain steady drug levels.
• Antacids and supplements: Take Dovato at least 2 hours before OR 6 hours after taking antacids, laxatives containing aluminum/magnesium/calcium, or buffered medications.
• Iron/calcium supplements: Can be taken together with Dovato if taken with food. Otherwise, apply the same 2-before/6-after rule.
• Swallow whole: Do not crush, chew, or split Dovato tablets.

Who Should NOT Take Dovato?

Dovato is contraindicated (should not be used) in certain situations:

• If you take dofetilide (Tikosyn) — a life-threatening drug interaction exists.
• If you are allergic to dolutegravir or lamivudine.
• If you are co-infected with HIV and hepatitis B (HBV) and Dovato is the only antiretroviral you're taking — additional HBV therapy is needed, or a different regimen should be considered.
• If you are in the first 12 weeks of pregnancy — dolutegravir has a known risk of neural tube defects.
• If your creatinine clearance (CrCl) is below 30 mL/min — Dovato's fixed dose cannot accommodate the lamivudine adjustment needed in severe kidney disease.

Is Dovato Effective?

Yes. Dovato's approval was based on the GEMINI-1 and GEMINI-2 Phase 3 trials, which demonstrated that dolutegravir plus lamivudine was non-inferior (equally effective) to a three-drug regimen of dolutegravir plus tenofovir/emtricitabine in treatment-naive adults. At 48 weeks, the proportion of patients with undetectable viral load was similar between groups.

The TANGO study further validated Dovato as a switch option for virologically suppressed patients. More recently, the PASO-DOBLE trial showed Dovato matched Biktarvy in viral suppression at 48 weeks, with potentially less weight gain in the Dovato group.

How Is Dovato Different From Other HIV Medications?

Dovato's key distinguishing feature is its two-drug design. Most other complete HIV regimens — including Biktarvy and Triumeq — use three drugs. The fewer-drug approach was controversial when Dovato launched, but years of clinical data have validated its efficacy for appropriate patients.

Two drugs means:

• Potentially fewer side effects from drug exposure.
• Fewer drug interactions to manage.
• Less long-term organ exposure (e.g., no tenofovir, reducing kidney and bone concerns associated with some TDF-based regimens).

The Bottom Line

Dovato is a once-daily, single-tablet, two-drug HIV treatment that has demonstrated equivalent efficacy to three-drug regimens in appropriate patients. It's well tolerated, convenient, and a standard first-choice option for many people living with HIV-1. To understand exactly how it works inside the body, read our guide on how Dovato works.